News

NeuroOne expects FY25 revenue to reach $8M–$10M as OneRF platform advances and new FDA submission broadens pipeline
Discover Q2 2025 insights for NeuroOne (NMTC), including 97% revenue growth, FDA submissions, and strategic partnerships fueling innovation and expansion.
Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development
CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...